Not FDA approved and sold as a research chemical. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Chonluten

Not FDA approved

Synthetic short peptide bioregulator

Evidence score

14/ 100

Thin evidence

Very thin human evidence

Regulatory standing. Sold as a research chemical, not approved
Animal / preclinical only. Evidence is largely animal or in-vitro
No registered human trials. Nothing registered on ClinicalTrials.gov
No sources. Nothing cited to verify

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Chonluten is a synthetic tripeptide (reported as Glu-Asp-Gly) from the family of short peptide bioregulators developed in Russia by the Khavinson group. It is described as being derived from bronchial and lung tissue, and proponents suggest it may influence gene expression in respiratory tissue, though this mechanism is not well established.

What the evidence shows

Automatic summaryAnimal / preclinical

There are no registered human trials, and the public literature is very limited, with roughly one indexed paper, mostly lab or animal work. Any effects in humans are unproven, and the available evidence is thin and largely from a single research group.

This name is shared with unrelated compounds in public databases, so trial and paper counts are not shown here, and the evidence score counts no registered trials. Treat this profile as a starting point only.

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.